Truist raised the firm’s price target on CG Oncology (CGON) to $66 from $62 and keeps a Buy rating on the shares after the company provided an updated timeline for PIVOT-006 topline data, now expected in 1H26. The accelerated pivotal readout was driven by “the unprecedented early completion of enrollment,” which the firm views as potentially reflecting physician buy-in for Creto, the analyst tells investors in a research note. The firm noted its peak revenue estimate of roughly $1.4B for Creto and a favorable setup, with surveillance as the control arm and a less crowded competitive landscape.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- CG Oncology rises 25.2%
- Midday Fly By: Job growth comes in below forecasts in December
- CG Oncology: Early PIVOT-006 Readout, Strengthened Creto Outlook, and 2026 Catalyst Wave Support Buy Rating and Higher $85 Target
- CG Oncology rises 16.0%
- CG Oncology Accelerates Phase 3 Bladder Cancer Trial Timeline